BioCentury | Sep 19, 2020
Product Development

Sept. 18 ESMO roundup: data from Incyte, Autolus, Merck, Alkermes and Daiichi

Incyte moving into Phase III with PD-1 inhibitor retifanlimab for SCACIncyte Corp. (NASDAQ:INCY) reported its PD-1 inhibitor retifanlimab led to an objective response rate of 14% and a disease control rate of 49% in the...
BioCentury | Sep 7, 2018
Clinical News

Fosun to start clinical testing in China for Yescarta

China's National Medical Products Administration (NMPA) approved an application from Fosun Pharma Kite Biotechnology Co. Ltd. to begin clinical testing of Yescarta axicabtagene ciloleucel to treat recurrent and refractory large B cell lymphoma. Fosun Kite...
BioCentury | Sep 4, 2018
Company News

Kymriah becomes first CAR T available on NHS England

Novartis AG (NYSE:NVS; SIX:NOVN) said it has reached an agreement with NHS England to make Kymriah tisagenlecleucel available in England, which the agency said marks Europe's first full access deal for a CAR T therapy....
BioCentury | Aug 31, 2018
Clinical News

CAR Ts Kymriah, Yescarta get green light in EU

The European Commission approved Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN) and Yescarta axicabtagene ciloleucel from the Kite Pharma Inc. subsidiary of Gilead Sciences Inc. (NASDAQ:GILD), making them the first approved CAR T therapies in...
BioCentury | Aug 27, 2018
Company News

CAR Ts Kymriah, Yescarta get green light in EU

The European Commission approved Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN) and Yescarta axicabtagene ciloleucel from the Kite Pharma Inc. subsidiary of Gilead Sciences Inc. (NASDAQ:GILD), making them the first approved CAR T therapies in...
BioCentury | May 1, 2018
Company News

Read says Pfizer not looking toward M&A

Pfizer Inc. (NYSE:PFE) Chairman and CEO Ian Read said the pharma is focusing investments on its own pipeline rather than M&A. "I don't see that we need a transformative deal, nor do I see one...
BioCentury | Apr 13, 2018
Financial News

Cellectis plans to use funds for UCART development and commercialization

Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) said it would use $100 million from a recent financing to establish a manufacturing facility for its UCART candidates. Cellectis also intends to use about $20 million to advance an additional...
BioCentury | Apr 6, 2018
Company News

Allogene gains Pfizer's off-the-shelf CAR T portfolio, announces $300M series A

Newly launched Allogene Therapeutics Inc. (South San Francisco, Calif.) will assume from Pfizer Inc. (NYSE:PFE) rights to off-the-shelf allogeneic CAR T products discovered by Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS). Allogene also unveiled a $300 million series...
BioCentury | Apr 6, 2018
Financial News

Cellectis raises $175M in follow-on

Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) raised $175 million on April 4 through the sale of 5.6 million shares at $31 in a follow-on underwritten by Goldman Sachs, Citigroup, Barclays, Nomura, Oppenheimer and Ladenburg Thalmann. On April...
BioCentury | Apr 5, 2018
Financial News

Cellectis reaps $175M in follow-on

Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) raised $175 million through the sale of 5.6 million shares at $31 in a follow-on underwritten by Goldman Sachs, Citigroup, Barclays, Nomura, Oppenheimer and Ladenburg Thalmann. The price is a 20%...
Items per page:
1 - 10 of 124